Massive french study to test if RSV antibody shot stops childhood wheezing

NCT ID NCT07317141

Not yet recruiting Prevention Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow over 200,000 infants in France to see if early immunization with nirsevimab, an antibody against RSV, reduces wheezing episodes in preschool years. Researchers will compare hospitalization rates for wheezing between immunized and non-immunized children. The goal is to understand if preventing RSV early can have long-term respiratory benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nirsevimab (a monoclonal antibody against RSV)
What this could lead to: If successful, this could show that giving nirsevimab early in life reduces wheezing and may lower the risk of asthma in later childhood.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. The study has not started yet, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA CHILDHOOD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood onset asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA CHILDHOOD INFANT WHEEZE PRESCHOOL AGE CHILDREN

Contacts and locations

Locations

Hospices Civils de Lyon - Hôpital Femme Mère Enfant

Bron, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.